Separate terms with OR to return results that match either term.
 
Clear All

611 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status (Descending)
C9118 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct. 1, 2002 Dec. 31, 2002 No Longer Used
C9284 Ipilimumab Yervoy 1mg Immunotherapy Checkpoint Inhibitor CTLA-4 No 2011 July 1, 2011 Dec. 31, 2011 No Longer Used
C9021 Obinutuzumab Gazyva 10 mg Immunotherapy Monoclonal Antibody CD20 No 2013 April 4, 2014 Dec. 31, 2014 No Longer Used
C9260 Ofatumumab Arzerra 10mg Immunotherapy Monoclonal Antibody CD20 No 2009 April 1, 2010 Dec. 31, 2010 No Longer Used
C9235 Panitumumab Vectibix 10mg Immunotherapy Monoclonal Antibody EGFR No 2006 Jan. 1, 2007 Dec. 31, 2007 No Longer Used
S0146 Peginterferon Alfa-2b Pegintron, Sylatron 20 mcg/mL Immunotherapy Cytokine Interferon No 2001 July 1, 2005 Sept. 30, 2010 No Longer Used
C9027 Pembrolizumab Keytruda 1 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2014 Jan. 1, 2015 Dec. 31, 2015 No Longer Used
C9292 Pertuzumab Perjeta 10 mg Immunotherapy Monoclonal Antibody HER2 No 2012 Oct. 1, 2012 Dec. 31, 2013 No Longer Used
C9025 Ramucirumab Cyramza 5 mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Oct. 1, 2014 Dec. 31, 2015 No Longer Used
C9455 Siltuximab Sylvant 10 mg Immunotherapy Monoclonal Antibody IL-6 No 2014 July 1, 2015 Dec. 31, 2015 No Longer Used
C9273 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Oct. 1, 2010 June 30, 2011 No Longer Used
C9216 Abarelix Plenaxis 10 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan. 1, 2005 No Longer Used
J0128 Abarelix Plenaxis 10 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan. 1, 2005 No Longer Used
S0165 Abarelix Plenaxis 100 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan. 1, 2005 No Longer Used
C9430 Leuprolide Acetate Eligard, Lupron Depot, Viadur, Lupron 1 mg Hormonal Therapy GnRH Agonist No 1995 Jan. 1, 2004 Jan. 1, 2006 No Longer Used
J1051 Medroxyprogesterone Acetate Depo-Provera, Depo-SubQ Provera 104, Provera 50 mg Hormonal Therapy Progestin No 1959 Jan. 1, 2003 Dec. 31, 2012 No Longer Used
NA Polyestradiol Phosphate Estradurin, Estradurine 40 mg Hormonal Therapy Estrogen Derivative No 1957 Aug. 8, 2003 No Longer Used
NA Testolactone Teslac 250 mg Hormonal Therapy Androgen Yes 1970 June 25, 2005 No Longer Used
J3120 Testosterone Enanthate Testosterone Enanthate 100 mg Hormonal Therapy Androgen No 1953 Jan. 1, 1982 Jan. 1, 2015 No Longer Used
J3130 Testosterone Enanthate Testosterone Enanthate 200 mg Hormonal Therapy Androgen No 1953 Jan. 1, 1982 Jan. 1, 2015 No Longer Used
J1440 Filgrastim Neupogen, Zarxio 300 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 1991 Jan. 1, 2014 Dec. 31, 2013 No Longer Used
J1441 Filgrastim Neupogen, Zarxio 480 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 1991 Jan. 1, 2014 Dec. 31, 2013 No Longer Used
J1446 Tbo-filgrastim Granix 5 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2015 Jan. 1, 2016 Dec. 31, 2015 No Longer Used
C9428 Mesna Mesna rescue, Mesnex, Mesna Novaplus, Uromitexan 200 mg Ancillary Therapy Chemoprotective Detoxifying Agent No 1988 Jan. 1, 2004 Dec. 31, 2005 No Longer Used
Q9978 Netupitant/palonostron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 July 1, 2015 Dec. 31, 2015 No Longer Used

Found 611 results in 3 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.